𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Specific immunotherapy of MUC1-positive adenocarcinomas with a recombinant vaccinia virus expressing MUC1 and IL-2

✍ Scribed by N Bizouarne, P Squiban, B Acres, JM Balloul, MA Ohresser, R Figlin…

Book ID
120700812
Publisher
BioMed Central
Year
2001
Tongue
English
Weight
293 KB
Volume
3
Category
Article
ISSN
1465-5411

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I immunotherapy with a modified va
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer
✍ Professor Christoph Rochlitz; Robert Figlin; Patrick Squiban; Marc Salzberg; Mik 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

## Abstract ## Background The MUC1 protein is a highly glycosylated mucin normally found at the apical surface of mucin‐secreting epithelial cells in many types of tissues. MUC1 is expressed, but heavily underglycosylated, in different human tumors. TG4010 is a viral suspension of a recombinant va

Expression of MUC1 and MUC2 mucin antige
Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: Its relationship with a new morphological classification of cholangiocarcinoma
✍ Michiyo Higashi; Suguru Yonezawa; Jenny J. L. Ho; Sadao Tanaka; Tatsuro Irimura; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 439 KB

Our previous immunohistochemical study on intrahepatic bile duct tumors showed that invasive cholangiocarcinoma (ICC) with a poor outcome expressed MUC1 mucin but was negative for MUC2 mucin, whereas bile duct cystadenocarcinoma (BDCC) with a favorable outcome was MUC1 negative and MUC2 positive. In